U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07864623) titled 'A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease' on Oct. 02.
Brief Summary: The primary purpose of this study is to evaluate the efficacy of LEQEMBI in participants with early Alzheimer's disease (AD) indicated per Canada Product Monograph (APOE4 non-carriers and heterozygotes; indicated population) compared with placebo (PBO)-treated participants from BAN2401-G000-301 (Study 301) Core study on change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment.
Study Start Date: Oct. 30
Study Type: OBSERVATIONAL
Condition:
Alzheimers Disease
Intervention:
OTHER: No Int...